- Home
- DXYZ vs RIGL Comparison
DXYZ vs RIGL Comparison
Compare DXYZ & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXYZ
- RIGL
- Stock Information
- Founded
- DXYZ N/A
- RIGL 1996
- Country
- DXYZ
- RIGL United States
- Employees
- DXYZ N/A
- RIGL N/A
- Industry
- DXYZ
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- DXYZ
- RIGL Health Care
- Exchange
- DXYZ Nasdaq
- RIGL Nasdaq
- Market Cap
- DXYZ 313.1M
- RIGL 335.5M
- IPO Year
- DXYZ 2024
- RIGL 2000
- Fundamental
- Price
- DXYZ $23.60
- RIGL $30.79
- Analyst Decision
- DXYZ
- RIGL Buy
- Analyst Count
- DXYZ 0
- RIGL 5
- Target Price
- DXYZ N/A
- RIGL $38.20
- AVG Volume (30 Days)
- DXYZ N/A
- RIGL 529.4K
- Earning Date
- DXYZ N/A
- RIGL 11-06-2025
- Dividend Yield
- DXYZ N/A
- RIGL N/A
- EPS Growth
- DXYZ N/A
- RIGL N/A
- EPS
- DXYZ N/A
- RIGL 5.43
- Revenue
- DXYZ N/A
- RIGL $267,921,000.00
- Revenue This Year
- DXYZ N/A
- RIGL $59.93
- Revenue Next Year
- DXYZ N/A
- RIGL N/A
- P/E Ratio
- DXYZ N/A
- RIGL $5.64
- Revenue Growth
- DXYZ N/A
- RIGL 105.62
- 52 Week Low
- DXYZ N/A
- RIGL $13.57
- 52 Week High
- DXYZ N/A
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- DXYZ 38.19
- RIGL 53.05
- Support Level
- DXYZ $25.00
- RIGL $26.38
- Resistance Level
- DXYZ $26.80
- RIGL $28.95
- Average True Range (ATR)
- DXYZ 1.64
- RIGL 1.47
- MACD
- DXYZ -0.20
- RIGL 0.48
- Stochastic Oscillator
- DXYZ 7.52
- RIGL 84.64
About DXYZ Destiny Tech100 Inc. Common Stock
Destiny Tech100 Inc is a non-diversified, closed-end management investment company. It invests in a portfolio of what is believed to be 100 of the top venture-backed private technology companies.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.